Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

It is administered through subcutaneous route. It acts by targeting interleukin-6. Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company that focuses on discovering, developing, and ...

Lastly, the company’s dividend looks well-covered with a payout ratio of under 50%. Novo Nordisk Is a Long-term Winner Despite the recent setback, Novo Nordisk is a long-term winner.

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...

executive vice president for development at Novo Nordisk, said in a company news release Friday. He said Novo Nordisk would use insights from the trial “to further explore the additional weight ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the ... of the drugmaker’s stock-market value. The Danish company—which had become Europe’s biggest by market ...